We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Dianthus Therapeutics Inc (DNTH) USD0.001

Sell:$15.01 Buy:$29.20 Change: $1.72 (7.08%)
Market closed |  Prices as at close on 13 May 2024 | Switch to live prices |
Sell:$15.01
Buy:$29.20
Change: $1.72 (7.08%)
Market closed |  Prices as at close on 13 May 2024 | Switch to live prices |
Sell:$15.01
Buy:$29.20
Change: $1.72 (7.08%)
Market closed |  Prices as at close on 13 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. Its product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile.

Contact details

Address:
300 Technology Square, 8Th Floor
CAMBRIDGE
02139
United States
Telephone:
+1 (857) 2012700
Website:
https://dianthustx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
DNTH
ISIN:
US2528281080
Market cap:
$712.88 million
Shares in issue:
29.35 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Leon Moulder
    Chairman of the Board
  • Marino Garcia
    President, Chief Executive Officer, Director
  • Ryan Savitz
    Chief Financial Officer, Treasurer
  • Edward Carr
    Chief Accounting Officer
  • Jeffrey Stavenhagen
    Chief Scientific Officer
  • Thomas Beetham
    Chief Legal Officer and Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.